Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration with Takeda

Shots:

• Egle has achieved the first milestone in its research agreement with Takeda, signed in June’2020. Egle will validate novel tumor-infiltrating regulatory T-cell targets while Takeda will develop the potential therapies
• Egle has leveraged its unique bioinformatic & translational capabilities to identify targets
• Following the achievement of the target identification, Egle will receive an R&D milestone payment & equity funding from Takeda

Click here ­to­ read full press release/ article | Ref: Businesswire| Image: Businesswire